Akkermansia muciniphila is a promising probiotic
By Ting Zhang, Qianqian Li, Lei Cheng, H. Buch, Faming Zhang. Microbial Biotechnology, 2019
614 citations recorded by the source corpus.
Akkermansia muciniphila (A. muciniphila), an intestinal symbiont colonizing in the mucosal layer, is considered to be a promising candidate as probiotics. A. muciniphila is known to have an important value in improving the host metabolic functions and immune responses. Moreover, A. muciniphila may have a value in modifying cancer treatment. However, most of the current researches focus on the correlation between A. muciniphila and diseases, and little is known about the causal relationship between them. Few intervention studies on A. muciniphila are limited to animal experiments, and limited studies have explored its safety and efficacy in humans. Therefore, a critical analysis of the current knowledge in A. muciniphila will play an important foundation for it to be defined as a new beneficial microbe. This article will review the bacteriological characteristics and safety of A. muciniphila, as well as its causal relationship with metabolic disorders, immune diseases and cancer therapy.
Subfields: Food Science, Infectious Diseases, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/fbf9ff8da0f6433c4327ea1e0a7400d3d1cef91b
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
Citations in the corpus
- Gut microbiota-derived metabolites as central regulators in metabolic disorders (2020, background): “98 A. muciniphila supplementation alone improves metabolic parameters in overweight/obese insulin-resistant volunteers characterised by better insulin sensitivity and a reduction in plasma total cholesterol levels and fat mass. 99 In mice, A. muciniphila promotes the production of SCFAs 100 and the…”